Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc REPCF


Primary Symbol: V.RP

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Oct 28, 2024 4:39pm
95 Views
Post# 36285745

RE:EVERYONE IN PRISON

RE:EVERYONE IN PRISONMetzger,
Non of us long term shareholders are happy with what is going on here but let's keep it civil.  References to God are offside here.

I agree that the management and directors of this company have mismanged this company to a point that it is seriously close to going under.  

We all thought Andrew Schutte and his father's company Mainpointe were the answer and would take the company to a revenue model from a reseach model.  This did not happen.

Looking back with 20/20 hindsight where things went wrong is when the management/directors decided to go all in with taking Shiseido to Arbitration regarding the original contract.  This Arbitration used up a substantial amount of working capital which could have been used to further advance the assets.  Instead, it was a 2 year stall of the company culminating in a lost Arbitration which had the affect of being the death of the company.  After the Arbitration loss the company was virtually bankrupt.
I hate this takeover deal but bankruptcy is a strong possibility if this takeover fails.

It pains me to admit that after close to 8 years of investing in this company my investment is completely lost.
 Hey Andrew Schutte prove me wrong.


<< Previous
Bullboard Posts
Next >>